Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug
Main Article Content
Keywords
primary axillary hyperhidrosis, retrometabolic anticholingeric drug
Abstract
N/A
References
1 Bodor N, Buchwald P. Retrometabolic Drug Design and Targeting. Wiley; 2013.
2 Ji F, Wu W, Dai X, et al. Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. J Pharm
Pharmacol. 2005;57(11):1427-1435. doi:10.1211/jpp.57.11.0008
3 Tóth-Sarudy E, Tóth G, Pallagi I, et al. Preparation and biological effects of pure stereoisomeric novel soft anticholinergics. Pharm. 2006;61(2):90-96.
4 Samir A, Ohura K, Bodor N, Imai T. Identification of Major Esterase Involved in Hydrolysis of Soft Anticholinergic (2R3’R-SGM) Designed From
Glycopyrrolate in Human and Rat Tissues. J Pharm Sci. 2019;108(8):2791-2797. doi:10.1016/j.xphs.2019.03.030
5 Kirsch B. An Open-Label, Repeat-Dose, Maximum-Use Study to Evaluate the Pharmacokinetics of Sofpironium Bromide Gel, 15% Topically Applied in Subjects with Primary Axillary Hyperhidrosis (Study BBI-4000-CL-102). Presented at the: Fall Clinical; November 29, 2020; Las Vegas, Nevada
2 Ji F, Wu W, Dai X, et al. Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate. J Pharm
Pharmacol. 2005;57(11):1427-1435. doi:10.1211/jpp.57.11.0008
3 Tóth-Sarudy E, Tóth G, Pallagi I, et al. Preparation and biological effects of pure stereoisomeric novel soft anticholinergics. Pharm. 2006;61(2):90-96.
4 Samir A, Ohura K, Bodor N, Imai T. Identification of Major Esterase Involved in Hydrolysis of Soft Anticholinergic (2R3’R-SGM) Designed From
Glycopyrrolate in Human and Rat Tissues. J Pharm Sci. 2019;108(8):2791-2797. doi:10.1016/j.xphs.2019.03.030
5 Kirsch B. An Open-Label, Repeat-Dose, Maximum-Use Study to Evaluate the Pharmacokinetics of Sofpironium Bromide Gel, 15% Topically Applied in Subjects with Primary Axillary Hyperhidrosis (Study BBI-4000-CL-102). Presented at the: Fall Clinical; November 29, 2020; Las Vegas, Nevada